Cencora, Inc. (NYSE:COR) Stock Position Raised by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 22.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220,517 shares of the company's stock after purchasing an additional 40,751 shares during the period. Russell Investments Group Ltd. owned approximately 0.11% of Cencora worth $49,546,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in shares of Cencora during the 4th quarter valued at $478,309,000. Raymond James Financial Inc. acquired a new position in shares of Cencora during the fourth quarter worth about $322,460,000. Amundi boosted its position in shares of Cencora by 30.8% in the fourth quarter. Amundi now owns 1,338,710 shares of the company's stock worth $318,385,000 after buying an additional 314,846 shares during the period. Nordea Investment Management AB grew its stake in shares of Cencora by 40.2% in the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after buying an additional 308,773 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Cencora by 43.8% during the 4th quarter. American Century Companies Inc. now owns 862,637 shares of the company's stock valued at $193,818,000 after buying an additional 262,823 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the transaction, the chairman now directly owns 317,913 shares in the company, valued at $85,680,732.63. The trade was a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,675 shares of company stock valued at $8,034,778 over the last three months. Company insiders own 10.80% of the company's stock.

Remove Ads

Cencora Price Performance

COR stock traded up $5.31 during trading hours on Friday, hitting $284.46. 1,509,188 shares of the stock traded hands, compared to its average volume of 1,506,610. The stock has a 50-day simple moving average of $260.27 and a 200 day simple moving average of $245.01. The company has a market cap of $55.16 billion, a P/E ratio of 40.46, a P/E/G ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Bank of America boosted their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday. Finally, Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus target price of $284.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.